EU standards snub to EFPIA over anti-counterfeiting highlights mistrust of industry
This article was originally published in Scrip
The European Department for the Quality of Medicines (EDQM) has rejected an invitation from the European pharmaceutical industry federation EFPIA to take part in a tender for the implementation of EFPIA's anti-counterfeiting system. EDQM's rejection of the offer – including a statement in which it says that a system run by "industry and business stakeholders" cannot adequately serve the interests of patients - reveals the current mistrust between governments and the pharmaceutical industry.
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.